StocktwitsEarnings
$WHWK Q3 '26 Earnings Results & Recap
Whitehawk Therapeutics believes its $169.7M in cash, cash equivalents and short-term investments will enable planned operations into the second half of 2028, and does not expect revenue for the foreseeable future.
